NYSE$DHR
Danaher Corp · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Danaher reported Q2 2025 sales of $5.94B with net earnings of $555M and diluted EPS of $0.77.
Second-quarter sales rose 3.5% to $5.94B as Biotechnology and Diagnostics core sales grew while Life Sciences declined. Net earnings were $555M, or $0.77 per diluted share, reflecting a $432M pretax intangible impairment in Life Sciences genomics. Adjusted results benefited from pricing and Western Europe strength, partially offset by softer China high-growth markets.
- Q2 sales $5.94B (+3.5% YoY); core sales +1.5%.
- Net earnings $555M; diluted EPS $0.77.
- Biotechnology and Diagnostics core growth; Life Sciences down.
- $432M pretax trade-name impairment in genomics consumables.
- Foreign exchange added ~2% to reported sales growth.
Headline financials
Revenue & EPS history
Danaher · Revenue · Quarterly
$5.94B
Forward guidance
Multi-industry and defense suppliers focus on backlog, program wins, and segment mix.
Tailwinds
- Defense and aerospace demand pipelines.
- Operational excellence and cost programs.
- Portfolio actions and R&D for next-gen platforms.
Headwinds
- Program timing and government budget cycles.
- Supply chain and labor constraints.
- FX on international revenue.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2025
+0.0%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+0.3%
Avg return
30 days after
42%
31 / 73 earnings
Positive
+7.0%
Q4 2020
Best reaction
-9.7%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.5% | -9.0% | -12.2% | |
| Q4 2025 | -5.4% | -7.5% | -11.6% | |
| Q3 2025 | +6.1% | +7.0% | +6.6% | |
| Q2 2025 | -0.4% | +5.2% | -4.0% | |
| Q1 2025 | +3.8% | +6.6% | +1.4% | |
| Q4 2024 | -9.7% | -11.1% | -17.9% | |
| Q3 2024 | -5.9% | -9.8% | -13.6% | |
| Q2 2024 | +5.9% | +9.2% | +6.8% | |
| Q1 2024 | +6.1% | +4.4% | +10.7% | |
| Q4 2023 | +2.6% | +5.7% | +9.7% | |
| Q3 2023 | -5.6% | -7.9% | +8.5% | |
| Q2 2023 | +2.7% | +0.8% | -1.7% | |
| Q1 2023 | -8.6% | -6.9% | -9.4% | |
| Q4 2022 | -5.1% | -4.0% | -8.8% | |
| Q3 2022 | -5.2% | -2.3% | +1.1% | |
| Q2 2022 | +7.0% | +8.0% | +14.2% | |
| Q1 2022 | -5.6% | -10.5% | -10.2% | |
| Q4 2021 | +5.4% | +5.4% | +3.0% | |
| Q3 2021 | -0.5% | -2.5% | -0.2% | |
| Q2 2021 | +4.1% | +3.9% | +14.9% | |
| Q1 2021 | +6.3% | +5.6% | +3.3% | |
| Q4 2020 | +7.0% | +3.3% | -6.1% | |
| Q3 2020 | +2.7% | +5.8% | -0.3% | |
| Q2 2020 | -0.2% | +1.7% | +6.2% | |
| Q1 2020 | -0.6% | -1.7% | +5.3% | |
| Q4 2019 | -2.6% | -1.5% | -12.5% | |
| Q3 2019 | -1.9% | -0.9% | +3.5% | |
| Q2 2019 | +1.4% | +2.0% | +0.5% | |
| Q1 2019 | +1.6% | +2.3% | +5.0% | |
| Q4 2018 | +2.8% | +2.8% | +18.9% | |
| Q3 2018 | -4.4% | -7.2% | -1.7% | |
| Q2 2018 | +2.5% | +4.8% | +2.0% | |
| Q1 2018 | -1.0% | -2.2% | -1.1% | |
| Q4 2017 | -2.3% | -1.6% | -5.8% | |
| Q3 2017 | +5.5% | +5.7% | +8.4% | |
| Q2 2017 | -3.2% | -4.4% | -5.7% | |
| Q1 2017 | -5.5% | -3.6% | -5.0% | |
| Q4 2016 | +4.0% | +3.4% | +7.8% | |
| Q3 2016 | +3.9% | +2.1% | +2.4% | |
| Q2 2016 | -0.2% | +0.2% | -0.8% | |
| Q1 2016 | +1.6% | — | — | |
| Q4 2015 | -0.2% | — | — | |
| Q3 2015 | +4.2% | — | — | |
| Q2 2015 | -0.1% | — | — | |
| Q1 2015 | -2.3% | — | — | |
| Q4 2014 | -1.0% | — | — | |
| Q3 2014 | +3.9% | — | — | |
| Q2 2014 | -4.3% | — | — | |
| Q1 2014 | -0.2% | — | — | |
| Q4 2013 | +1.4% | — | — | |
| Q3 2013 | +4.1% | — | — | |
| Q2 2013 | +0.4% | — | — | |
| Q1 2013 | -1.1% | — | — | |
| Q4 2012 | -1.2% | — | — | |
| Q3 2012 | -4.9% | — | — | |
| Q2 2012 | -1.9% | — | — | |
| Q1 2012 | -2.8% | — | — | |
| Q4 2011 | -0.6% | — | — | |
| Q3 2011 | +6.4% | — | — | |
| Q2 2011 | -3.1% | — | — | |
| Q1 2011 | -2.1% | — | — | |
| Q4 2010 | +1.8% | — | — | |
| Q4 2007 | +1.8% | — | — | |
| Q3 2010 | +3.8% | — | — | |
| Q2 2010 | -4.4% | — | — | |
| Q1 2009 | +4.8% | — | — | |
| Q1 2010 | +0.4% | — | — | |
| Q4 2009 | -0.1% | — | — | |
| Q3 2009 | -0.8% | — | — | |
| Q3 2008 | -0.8% | — | — | |
| Q2 2009 | -2.4% | — | — | |
| Q2 2008 | -2.4% | — | — | |
| Q4 2008 | -2.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro